Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis

American Journal of Respiratory and Critical Care Medicine

Volumn 167, Issue 11, 2003, Pages 1472-1477

  Yee, Daphne ^a   Valiquette, Chantal ^a   Pelletier, Marthe ^a   Parisien, Isabelle ^a   Rocher, Isabelle ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Adverse drug reactions; Side effects; Tuberculosis treatment

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ARTHRALGIA; ARTICLE; ASIA; DRUG FEVER; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RASH; RISK FACTOR; SIDE EFFECT; TUBERCULOSIS; VISUAL DISORDER; VOMITING; DRUG ERUPTION; LUNG TUBERCULOSIS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; TOXIC HEPATITIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DRUG ERUPTIONS; ETHAMBUTOL; FEMALE; HEPATITIS, TOXIC; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; ISONIAZID; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRAZINAMIDE; RIFAMPIN; RISK FACTORS; TUBERCULOSIS, PULMONARY;

EID: 0038471208     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200206-626OC     Document Type: Article

References (34)

1. Kopanoff DE, Snider DE, Caras GJ. Isoniazid-related hepatitis. Am Rev Respir Dis 1978;117:991-1001.
2. Franks AL, Binkin NJ, Snider DE, Rokaw WM, Becker S. Isoniazid hepatitis among pregnant and postpartum hispanic patients. Public Health Rep 1989;104:151-155.
3. Durand F, Bernuau J, Pessayre D, Samuel D, Belaiche J, Degott C, Bismuth H, Belghiti J, Erlinger S, Rueff B, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995;21:929-932.
4. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996;9:2026-2030.
5. Nolan CM, Goldberg SV, Buskin SE. Hepatoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA 1999;281:1014-1018.
6. Van den Brande P, Steenbergen WV, Verdoot G, Demedts M. Aging and hepatoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995;152:1705-1708.
7. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. Chest 1991;99:465-471.
8. Leibold JE. The ocular toxicity of ethambutol and its relation to dose. Ann N Y Acad Sci 1966;135:904-909.
9. American Thoracic Society. Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1994;149: 1359-1374.
10. Combs DL, O'Brien RJ, Geiter LJ. USPHS tuberculosis short course chemotherapy trial 21: effectiveness, toxicity, and acceptability. Ann Intern Med 1990;112:397-406.
11. British Thoracic Association. A controlled trial of 6-months isoniazid and rifampin therapy for pulmonary tuberculosis: first report: results during drug therapy. Br J Dis Chest 1981;75:141-153.
12. Zierski M, Bek E. Side-effects of drug regimens used in short-course chemotherapy for pulmonary tuberculosis: a controlled clinical study. Tubercle 1980;61:41-49.
13. Ormerod LP, Horsfield N. Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. Tuber Lung Dis 1996; 77:37-42.
14. Dossing M, Wilcke TR, Askgaard DS, Nyboo B. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77: 335-340.
15. Danan G, Pessayre D, Larrey D, Benhamou JP. Pyrazinamide fulminant hepatitis: an old hepatotoxin strikes again. Lancet 1981;7:1056-1057.
16. Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, Echizen H, Ogata H. Risk factors for antituberculous chemotherapy-induced hepatotpxicity in Japanese pediatric patients. Clin Pharmacol Ther 2002;72:220-226.
17. American Thoracic Society. Centers for Disease Control and Prevention. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations. MMWR 2001;50:733-735.
18. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, King MD, Kawamura LM, Hopewell PC. Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002;137:640-647.
19. Lee AM, Mennone JZ, Jones RC, Paul WS. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002;6:995-1000.
20. Dawson-Saunders B, Trapp RG. Basic and clinical biostatistics. Norwalk: Appleton & Lange; 1990.
21. Cox DR. Regression models and life-tables [with discussion]. J. R. Stat. Soc. B 1972;34:187-220.
22. Gonzalez Montaner LJ, Dambrosi A, Manassero M, Dambrosi V, Dambrosi ML. Adverse effects of antituberculosis drugs causing changes in treatment. Tubercle 1982;63:291-294.
23. Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, Nyirenda O, Luo N, Pobee J, Elliott AM, McAdam KP, Porter JD. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998;12:2447-2457.
24. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, Contave M, Johnson M, Davis H, Geiter L, Johnson E, Huebner R, Boulos R, Chaisson RE. Randomized trial of isoniazid versus rifampin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet 1998;351:786-792.
25. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, Valdespino JL, Coberly J, Schechter M, Klukowicz AJ, Barry MA, O'Brien RJ. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. JAMA 2000;283:1445-1450.
26. Lou HX, Shullo MA, McKaveney TP. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population. Pharmacotherapy 2002;22:701-704.
27. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multi-drug-resistant tuberculosis. CMAJ 2002;167: 131-136.
28. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969;17:28-106.
29. Garibaldi RA, Drustin RE, Ferebee SH, Gregg MB. Isoniazid-associated hepatitis. Am Rev Respir Dis 1972;106:357-365.
30. Israel HL. Isoniazid-associated hepatitis: reconsideration of the indication for administration of isoniazid. Gastroenterology 1975;69:539-542.
31. Burman WJ, Reves RR. Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers. Am J Respir Crit Care Med 2001;164:1112-1113.
32. Teleman MD, Chee CBE, Earnest A, Wang YT. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. IUATLD. Int. J. Tuberc. Lung Dis. 2002;6:699-705.
33. Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-919.
34. Hong Kong Chest Service/Tuberculosis Research Centre, MBMRC. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992;145:36-41.